Description
This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:
- Compares traditional ultrasound with advanced imaging techniques.
- Examines AI-based approaches in patient classification.
The episode concludes with a forward-looking perspective on the future management of MASLD.
Faculty
- Thomas Berg (Moderator)
- Timm Denecke (Faculty)
- Juan-Manuel Pericàs (Faculty)
- Valérie Vilgrain (Faculty)
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Related episodes
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
ℹ️ Please click here to watch this EASL Studio episode.